Our airways are lined with a thin layer of mucus, which traps viruses, bacteria and foreign particles and clears them away. However, excessive mucus production, as seen in many inflammatory lung conditions such as asthma, cystic fibrosis or COPD, can block the airways and, in some cases, severely impair lung function. Until now, most treatments have aimed to reduce inflammation and widen the airways. An international research team has now developed a novel drug that intervenes directly in this process and prevents the excessive release of mucins (the main component of mucus) – whilst preserving the vital, healthy underlying layer of mucus. Preliminary experimental work on genetically modified mice had shown that mice lacking a specific protein (synaptotagmin-2) do not exhibit excessive mucus secretion in the airways, neither during inflammatory processes nor during allergic reactions. Subsequently, a substance (SP9) was developed that binds to this protein and thereby inhibits it. In fact, the researchers also succeeded in finding a way to deliver the new drug into the cells responsible for mucus secretion. Its efficacy has already been demonstrated in chronically inflamed human airway epithelium in cell culture. The next step is to determine whether the mucus inhibitor is suitable for treating patients with chronic conditions and whether it can be administered in sufficient concentrations via a spray. Clinical trials are set to begin in two to three years. Reference: University of Ulm, Stanford University, MD Anderson Cancer Centre, Texas. Inhibition of calcium-triggered secretion by hydrocarbon-stapled peptides, Nature 2022; https://www.nature.com/articles/s41586-022-04543-1
Inhibitor stops excessive mucus build-up